Neuropeptide S

Overview

Neuropeptide S (NPS) was identified in 2004 by Yun-Lu Xu and colleagues in the Civelli laboratory through deorphanization of GPR154, a putative GPCR previously associated with asthma susceptibility in genetic studies. The name "neuropeptide S" reflects the distinctive N-terminal serine residue at position 1 — a configuration that is unusual among mammalian neuropeptides and proved critical for receptor activation.

NPS has an unusual physiological profile: it simultaneously promotes wakefulness and arousal (like orexin-A) while also producing anxiolytic effects (unlike most arousal-promoting peptides, which tend to increase anxiety). This combination has made NPS a peptide of significant interest in sleep, anxiety, and addiction research.

NPS-expressing neurons form a small, discrete cluster in the brainstem near the locus coeruleus — specifically in the pericoerulear region, the principal sensory trigeminal nucleus, and the lateral parabrachial nucleus. From these sources, NPS fibers project broadly to amygdala, hypothalamus, thalamus, and cortical regions. Its receptor NPSR1 (formerly GPR154) is expressed throughout these projection targets. The NPSR1 gene contains a functional polymorphism (Asn107Ile) that increases receptor sensitivity to NPS and has been associated with various behavioral and respiratory phenotypes in human association studies.

Structure/Sequence

Human NPS: SFRNGVGTGMKKTSFQRAKS

• Length: 20 amino acids
• Molecular weight: ~2,189 g/mol
• Gene: NPS (chromosome 10q26.2)
• N-terminal serine: Absolutely critical for receptor activation — the "S" in NPS
• Species conservation: Highly conserved across mammals, particularly N-terminal region
• Not amidated: Unlike many neuropeptides, NPS has a free C-terminus

Critical Residues

• Ser1: Any substitution drastically reduces potency; the free N-terminal amine and hydroxyl form essential contacts with the receptor
• Phe2: Hydrophobic contact
• N-terminal hexapeptide (SFRNGV): Minimum sequence for partial agonism

Precursor

The 89-amino acid prepro-NPS precursor undergoes signal peptide cleavage and processing to yield the mature 20-aa NPS. No other bioactive products have been identified from the precursor.

Mechanism of Action

NPSR1 Receptor

NPS signals through a single receptor, NPSR1 (NPS Receptor 1, GPR154, GPRA):

• G-protein coupling: Dual Gq and Gs coupling
• Activates phospholipase C (via Gq): IP3 production, calcium mobilization
• Activates adenylyl cyclase (via Gs): cAMP elevation
• Calcium + cAMP dual signaling distinguishes NPSR1 from many unimodal GPCRs

Asn107Ile Polymorphism

A common human polymorphism (rs324981) at position 107 of NPSR1 produces an isoform that is ~10-fold more sensitive to NPS than the ancestral form. This variant has been associated with:

• Altered anxiety-related traits
• Sleep phenotypes (possibly reduced need for sleep)
• Asthma and rhinitis risk (original association leading to the gene's discovery)

Arousal and Wakefulness

• ICV NPS dose-dependently increases wakefulness
• Reduces non-REM and REM sleep
• Effects mediated through projections to arousal-promoting nuclei
• Activity complementary to orexin-A but through a distinct receptor system

Anxiolysis

• ICV NPS reduces anxiety-like behavior in multiple rodent assays (elevated plus maze, open field, light-dark box)
• Effects mediated through projections to amygdala (particularly medial amygdala)
• Paradoxical profile: arousal-promoting + anxiety-reducing
• The dissociation of arousal and anxiety has made NPS of interest as a conceptual template for anxiolytics that don't sedate

Fear Extinction and Addiction

• NPS facilitates fear extinction in conditioned fear paradigms
• Modulates drug-seeking behavior in reinstatement models
• Interactions with stress and HPA axis circuitry

Feeding

• Modest effects on food intake (generally suppression)

Research Summary

Common Discussion Topics

1. Arousal without anxiety — NPS's dissociation of wakefulness promotion from anxiogenesis is conceptually important. Most arousal-promoting systems (norepinephrine, orexins, CRH) increase anxiety as well. NPS suggests this coupling is not obligatory and has motivated medicinal chemistry efforts for non-sedating anxiolytics.

2. Asn107Ile human variant — The common NPSR1 polymorphism has enabled human association studies that complement rodent mechanistic work. Associations with asthma, sleep duration, and anxiety phenotypes suggest that human NPS signaling variability has functional consequences.

3. Discrete NPS nucleus — Unlike many neuropeptides expressed across multiple brain regions, NPS-producing neurons form a compact cluster in the brainstem. This anatomical specificity has enabled circuit-level manipulation (optogenetic and chemogenetic) to map NPS function.

4. Comparison to orexin-A — Both orexin-A and NPS promote wakefulness, but through different brainstem nuclei and different receptor systems. NPS's additional anxiolytic action contrasts with orexin's anxiogenic effects, even though both increase arousal.

5. Dual Gq/Gs signaling — NPSR1's coupling to both Gq and Gs is unusual and may contribute to NPS's distinctive behavioral profile. The simultaneous elevation of calcium and cAMP may engage different cellular programs than either pathway alone.

Related Compounds

• Orexin-A — complementary arousal-promoting peptide with different behavioral profile
• Cortistatin — sleep-promoting counterweight
• DSIP — delta sleep-inducing peptide
• Neuropeptide Y — related anxiolytic peptide with different mechanism